Table 1.
Characteristic of patients cohort
| Non-Shock (n = 769) | Developed Shock (n = 101) | P value | |
|---|---|---|---|
| Age,year[M(IQR)] | 64(55–74) | 63(55–73) | 0.52 |
| Male sex,n(%) | 610(79.3) | 76(75.6) | 0.35 |
| Anterior myocardial infarction,n(%) | 389(50.6) | 58(57.6) | 0.2 |
| Hypertension,n(%) | 505(65.7) | 69(68.8) | 0.60 |
| Diabetes,n(%) | 215(28.0) | 34(33.3) | 0.23 |
| Prior Stroke,n(%) | 101(13.1) | 30(30.3) | < 0.001 |
| Hyperlipidemia,n(%) | 64(9.7) | 9(9.1) | 0.84 |
| Smoke,n(%) | 450(58.5) | 53(52.1) | 0.25 |
| Prior myocardial infarction, n(%) | 73(9.53) | 8(7.98) | 0.61 |
| Creatinine,μmol/L[M(IQR)] | 72(62–87) | 69(60–81) | 0.22 |
| EF,%[M(IQR)] | 47(41–50) | 44(40–48) | 0.03 |
| Triglyceride, mmol/L[M(IQR)] | 1.38(1.00–2.05) | 1.39(0.90–2.10) | 0.72 |
| Cholesterol, mmol/L[M(IQR)] | 4.28(3.63–4.98) | 4.49(3.83–4.88) | 0.46 |
| LDL-C, mmol/L[M(IQR)] | 2.31(1.84–2.80) | 2.29(1.91–2.79) | 0.93 |
| HDL-C, mmol/L[M(IQR)] | 0.93(0.76–1.14) | 0.91(0.77–1.11) | 0.79 |
| Pre-procedure SBP, mmHg[M(IQR)] | 123(112–138) | 104(96–108) | < 0.001 |
| Pre-procedure HR, bpm[M(IQR)] | 79(69–89) | 91(82–100) | 0.008 |
| Total ischemic time,min[M(IQR)] | 342(234–610) | 360(267–713) | 0.26 |
| Killips class II/III, n(%) | 185(24.0) | 30(28.7) | 0.50 |
| Double vessel disease, n(%) | 310(40.3) | 34(33.3) | 0.20 |
| Triple vessel disease, n(%) | 235(30.6) | 40(39.4) | 0.07 |
| IRA | |||
| LAD, n(%) | 389(50.6) | 58(57.6) | 0.20 |
| LCX/OM, n(%) | 123(16) | 1(0.99) | < 0.001 |
| RCA, n(%) | 195(25.4) | 43(42.4) | < 0.001 |
| PDA/PL, n(%) | 65(8.5) | 0 | – |
| PTCA, n(%) | 12(1.51) | 0 | – |
| Stents | |||
| Sirolimus, n(%) | 481(62.6) | 58(57.6) | 0.32 |
| Everolimus, n(%) | 231(30.1) | 30(30.3) | 0.95 |
| Zotarolimus, n(%) | 155(20.1) | 24(24.2) | 0.40 |
| Paclitaxel, n(%) | 6(0.76) | 0 | – |
| Mediction | |||
| Aspirin, n(%) | 769(100) | 101(100%) | 1.00 |
| Clopidogrel, n(%) | 516(67.1) | 64(63.4) | 0.45 |
| Ticagrelor, n(%) | 253(32.9) | 37(36.6) | 0.45 |
| ACEI/ARB, n(%) | 511(66.5) | 64(63.6) | 0.54 |
| β-blocker, n(%) | 606(78.8) | 70(69.4) | < 0.001 |
| Spironolactone, n(%) | 442(57.5) | 63(62.7) | 0.35 |
| Diuretics, n(%) | 359(46.7) | 55(54.5) | 0.14 |
| Statin, n(%) | 767(99.8) | 100(99.6) | 0.31 |
EF ejection fraction, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, SBP systolic blood pressure, HR heart rate, IRA infarct related artery, LAD left anterior descending branch, LCX left circumflex branch, OM obtuse marginal branch, RCA right coronary artery, PDA posterior descending artery, PL posterior branch of left venticule, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker